BALPHARMA Latest Share Price (BALPHARMA)
TODAY IN ONE LINE
With a market cap of ₹134.21 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
BALPHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Steady Dividend YieldReliable 1.36% dividend yield
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 33.5% YoY
- ●Poor Capital ReturnsLow ROE of 6.5%
Latest BALPHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
BALPHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for BALPHARMA, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
BALPHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for BALPHARMA — derived from the latest tape, not yesterday's close.
BALPHARMA last traded at ₹106.79 with an intraday range of ₹105.11–₹109.79 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹106.79| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 118.71 | +11.92 | +11.16% |
| R3 | 114.03 | +7.24 | +6.78% |
| R2 | 111.91 | +5.12 | +4.79% |
| R1 | 109.35 | +2.56 | +2.40% |
| PIVOT | 107.23 | 0.44 | 0.41% |
| CURRENT | 106.79 | — | — |
| S1 | 104.67 | -2.12 | -1.99% |
| S2 | 102.55 | -4.24 | -3.97% |
| S3 | 99.99 | -6.80 | -6.37% |
| S4 | 95.31 | -11.48 | -10.75% |
BALPHARMA is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹–₹
Trading Inside opening range
BALPHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for BALPHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
BALPHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹134.21 Cr. and reported EPS of ₹0.71.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 312 | 312 ▲ 0.0% |
| Sales Growth YoY %Derived | 2.83% | 2.83% |
| Other Income | 2 | 2 ▲ 0.0% |
| Total Income | 314 | 314 ▲ 0.0% |
| 158 | 158 ▲ 0.0% | |
| Gross ProfitDerived | 154 | 154 ▲ 0.0% |
| Gross Margin %Derived | 49.32% | 49.32% |
| 122 | 122 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 32 | 32 ▲ 0.0% |
| OPM %Derived | 10.24% | 10.24% |
| 28 | 28 ▲ 0.0% | |
| Profit Before Tax (PBT) | 6 | 6 ▲ 0.0% |
| -0 | -0 ▲ 0.0% | |
| Effective Tax %Derived | -6.51% | -6.51% |
| Total Profit for Period | 6 | 6 ▲ 0.0% |
| Less: Non-controlling Interests | 0 | 0 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 6 | 6 ▲ 0.0% |
| Net Profit Margin %Derived | 2.02% | 2.02% |
| PAT Growth YoY %Derived | -12.49% | -12.49% |
| Earnings Per Share (EPS ₹) | 3.95 | 3.95 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 308 | 308 ▲ 0.0% |
| Material Cost % of RevenueDerived | 51.65% | 51.65% |
| Employee Cost % of RevenueDerived | 21.33% | 21.33% |
| Other Cost % of RevenueDerived | 17.75% | 17.75% |
| Interest Coverage (x)Derived | 1.24x | 1.24x |
| Period | Mar 2018 | Jul 2018 | Mar 2020 | Sept 2020 | Mar 2021 | Mar 2022 | Apr 2022 | May 2022 | Mar 2023 | May 2023 | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 212 | 212 ▲ 0.0% | 171 ▼ 19.2% | 171 ▲ 0.0% | 251 ▲ 46.4% | 281 ▲ 12.2% | 251 ▼ 10.9% | 281 ▲ 12.2% | 304 ▲ 8.2% | 304 ▲ 0.0% | 339 ▲ 11.5% | 339 ▲ 0.0% | 303 ▼ 10.7% | 303 ▲ 0.0% | 312 ▲ 2.8% | 312 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | — | — | 46.43% | 12.25% | — | — | 8.18% | 8.18% | 11.51% | 11.51% | -10.65% | -10.65% | 2.83% | 2.83% | |
| Other Income | 2 | 2 ▲ 0.0% | 2 ▲ 16.8% | 2 ▲ 0.0% | 1 ▼ 38.1% | 5 ▲ 352.6% | 1 ▼ 77.9% | 5 ▲ 352.6% | 1 ▼ 81.7% | 1 ▲ 0.0% | 3 ▲ 202.8% | 3 ▲ 0.0% | 2 ▼ 22.7% | 2 ▲ 0.0% | 2 ▼ 12.5% | 2 ▲ 0.0% | |
| Total Income | 213 | 213 ▲ 0.0% | 173 ▼ 18.9% | 173 ▲ 0.0% | 252 ▲ 45.5% | 286 ▲ 13.8% | 252 ▼ 12.1% | 286 ▲ 13.8% | 305 ▲ 6.6% | 305 ▲ 0.0% | 342 ▲ 12.1% | 342 ▲ 0.0% | 305 ▼ 10.8% | 305 ▲ 0.0% | 314 ▲ 2.7% | 314 ▲ 0.0% | |
99 | 99 ▲ 0.0% | 84 ▼ 15.3% | 84 ▲ 0.0% | 151 ▲ 79.4% | 168 ▲ 11.0% | 151 ▼ 9.9% | 168 ▲ 11.0% | 173 ▲ 3.1% | 173 ▲ 0.0% | 192 ▲ 11.0% | 192 ▲ 0.0% | 158 ▼ 17.7% | 158 ▲ 0.0% | 158 ▲ 0.0% | 158 ▲ 0.0% | ||
| Gross ProfitDerived | 112 | 112 ▲ 0.0% | 87 ▼ 22.6% | 87 ▲ 0.0% | 100 ▲ 14.5% | 114 ▲ 14.2% | 100 ▼ 12.4% | 114 ▲ 14.2% | 131 ▲ 15.6% | 131 ▲ 0.0% | 147 ▲ 12.2% | 147 ▲ 0.0% | 145 ▼ 1.5% | 145 ▲ 0.0% | 154 ▲ 5.9% | 154 ▲ 0.0% | |
| Gross Margin %Derived | 53.08% | 53.08% | 50.83% | 50.83% | 39.75% | 40.43% | 39.75% | 40.43% | 43.21% | 43.21% | 43.47% | 43.47% | 47.90% | 47.90% | 49.32% | 49.32% | |
95 | 95 ▲ 0.0% | 82 ▼ 13.5% | 82 ▲ 0.0% | 75 ▼ 8.6% | 90 ▲ 20.1% | 75 ▼ 16.7% | 90 ▲ 20.1% | 106 ▲ 17.9% | 106 ▲ 0.0% | 116 ▲ 9.0% | 116 ▲ 0.0% | 116 ▼ 0.3% | 116 ▲ 0.0% | 122 ▲ 5.3% | 122 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 17 | 17 ▲ 0.0% | 5 ▼ 72.6% | 5 ▲ 0.0% | 24 ▲ 413.8% | 23 ▼ 4.0% | 24 ▲ 4.2% | 23 ▼ 4.0% | 25 ▲ 7.0% | 25 ▲ 0.0% | 32 ▲ 25.5% | 32 ▲ 0.0% | 30 ▼ 6.2% | 30 ▲ 0.0% | 32 ▲ 7.9% | 32 ▲ 0.0% | |
| OPM %Derived | 8.19% | 8.19% | 2.78% | 2.78% | 9.76% | 8.35% | 9.76% | 8.35% | 8.26% | 8.26% | 9.29% | 9.29% | 9.75% | 9.75% | 10.24% | 10.24% | |
16 | 16 ▲ 0.0% | 20 ▲ 25.5% | 20 ▲ 0.0% | 21 ▲ 6.8% | 19 ▼ 9.5% | 21 ▲ 10.5% | 19 ▼ 9.5% | 21 ▲ 9.6% | 21 ▲ 0.0% | 25 ▲ 18.8% | 25 ▲ 0.0% | 27 ▲ 5.1% | 27 ▲ 0.0% | 28 ▲ 4.8% | 28 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 3 | 3 ▲ 0.0% | -14 ▼ 569.3% | -14 ▲ 0.0% | 4 ▲ 130.3% | 9 ▲ 123.8% | 4 ▼ 55.3% | 9 ▲ 123.8% | 5 ▼ 48.3% | 5 ▲ 0.0% | 9 ▲ 90.5% | 9 ▲ 0.0% | 5 ▼ 43.2% | 5 ▲ 0.0% | 6 ▲ 15.5% | 6 ▲ 0.0% | |
3 | 3 ▲ 0.0% | -1 ▼ 125.4% | -1 ▲ 0.0% | -1 ▲ 4.4% | 3 ▲ 670.5% | -1 ▼ 117.5% | 3 ▲ 670.5% | 2 ▼ 38.8% | 2 ▲ 0.0% | 2 ▼ 24.8% | 2 ▲ 0.0% | -2 ▼ 231.1% | -2 ▲ 0.0% | -0 ▲ 81.6% | -0 ▲ 0.0% | ||
| Effective Tax %Derived | 86.94% | 86.94% | 4.71% | 4.71% | -14.86% | 37.87% | -14.86% | 37.87% | 44.84% | 44.84% | 17.70% | 17.70% | -40.87% | -40.87% | -6.51% | -6.51% | |
| Total Profit for Period | 0 | 0 ▲ 0.0% | -13 ▼ 3524.1% | -13 ▲ 0.0% | 5 ▲ 136.6% | 6 ▲ 21.1% | 5 ▼ 17.4% | 6 ▲ 21.1% | 3 ▼ 54.1% | 3 ▲ 0.0% | 7 ▲ 184.3% | 7 ▲ 0.0% | 7 ▼ 3.3% | 7 ▲ 0.0% | 6 ▼ 12.2% | 6 ▲ 0.0% | |
| Less: Non-controlling Interests | — | — | — | — | -0 | 0 ▲ 409.3% | -0 ▼ 132.3% | 0 ▲ 409.3% | — ▼ 100.0% | — | 0 | 0 ▲ 0.0% | 0 ▼ 60.2% | 0 ▲ 0.0% | 0 ▲ 71.4% | 0 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 0 | 0 ▲ 0.0% | -13 ▼ 3524.1% | -13 ▲ 0.0% | 5 ▲ 136.8% | 6 ▲ 18.3% | 5 ▼ 15.5% | 6 ▲ 18.3% | 3 ▼ 53.3% | 3 ▲ 0.0% | 7 ▲ 182.2% | 7 ▲ 0.0% | 7 ▼ 2.9% | 7 ▲ 0.0% | 6 ▼ 12.5% | 6 ▲ 0.0% | |
| Net Profit Margin %Derived | 0.18% | 0.18% | -7.53% | -7.53% | 1.89% | 2.00% | 1.89% | 2.00% | 0.86% | 0.86% | 2.18% | 2.18% | 2.37% | 2.37% | 2.02% | 2.02% | |
| PAT Growth YoY %Derived | — | — | — | — | 136.79% | 18.32% | — | — | -53.32% | -53.32% | 182.21% | 182.21% | -2.86% | -2.86% | -12.49% | -12.49% | |
| Earnings Per Share (EPS ₹) | 0.27 | 0.27 ▲ 0.0% | -9.10 ▼ 3470.4% | -9.10 ▲ 0.0% | 3.20 ▲ 135.2% | 3.78 ▲ 18.1% | 3.20 ▼ 15.3% | 3.78 ▲ 18.1% | 1.67 ▼ 55.8% | 1.67 ▲ 0.0% | 4.68 ▲ 180.2% | 4.68 ▲ 0.0% | 4.53 ▼ 3.2% | 4.53 ▲ 0.0% | 3.95 ▼ 12.8% | 3.95 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 4.6% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 2 ▲ 5.9% | 2 ▲ 0.0% | 2 ▲ 0.7% | 2 ▲ 0.0% | 2 ▲ 0.7% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | — | — | — | — | — | — | — | — | — | -0 | -0 ▲ 0.0% | — ▲ 100.0% | — | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 0.0% | -0 ▼ 20.9% | -0 ▲ 0.0% | 0 ▲ 170.4% | 0 ▼ 98.5% | 0 ▲ 6487.1% | 0 ▼ 98.5% | — ▼ 100.0% | — | 0 | 0 ▲ 0.0% | — ▼ 100.0% | — | 0 | 0 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 210 | 210 ▲ 0.0% | 186 ▼ 11.4% | 186 ▲ 0.0% | 248 ▲ 32.8% | 277 ▲ 12.0% | 248 ▼ 10.7% | 277 ▲ 12.0% | 300 ▲ 8.4% | 300 ▲ 0.0% | 333 ▲ 10.9% | 333 ▲ 0.0% | 300 ▼ 9.9% | 300 ▲ 0.0% | 308 ▲ 2.5% | 308 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 48.62% | 48.62% | 42.20% | 42.20% | 54.07% | 58.32% | 54.07% | 58.32% | 58.90% | 58.90% | 53.53% | 53.53% | 49.45% | 49.45% | 51.65% | 51.65% | |
| Employee Cost % of RevenueDerived | 22.28% | 22.28% | 29.47% | 29.47% | 16.72% | 16.80% | 16.72% | 16.80% | 18.18% | 18.18% | 17.80% | 17.80% | 20.59% | 20.59% | 21.33% | 21.33% | |
| Other Cost % of RevenueDerived | 22.60% | 22.60% | 18.58% | 18.58% | 13.27% | 15.28% | 13.27% | 15.28% | 16.77% | 16.77% | 16.38% | 16.38% | 17.56% | 17.56% | 17.75% | 17.75% | |
| Interest Coverage (x)Derived | 1.14x | 1.14x | -0.23x | -0.23x | 1.25x | 1.39x | 1.25x | 1.39x | 1.31x | 1.31x | 1.41x | 1.41x | 1.17x | 1.17x | 1.24x | 1.24x |
BALPHARMA segment analysis : revenue and profit mix.
Disclosed business segments at BALPHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
BALPHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for BALPHARMA.
Our AI distills the core fundamental drivers supporting BALPHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
BALPHARMA's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating cash flow ₹30.83 Cr FY2026 recovered, demonstrating improved cash generation capability.
P/E 20.36x trades below peer median 30–40x, offering potential value entry point.
Low beta 0.88 indicates defensive characteristics during market volatility periods.
Dividend yield 1.37% provides steady income for conservative investors seeking returns.
Broad product portfolio across 30+ countries enables geographic revenue diversification.
Key Risks.
Latest quarterly EPS declined 46.6% YoY despite revenue growth, signaling profitability stress.
TTM EPS declined 33.5% YoY, indicating sustained earnings momentum deterioration.
Latest quarterly sales declined 11.40% YoY, showing weakening domestic demand pressures.
Latest quarterly net profit declined 19.20% YoY, compounding profitability concerns significantly.
Net debt ₹151.55 Cr represents 143% of FY2026 net profit, creating refinancing risk.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.98. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.68%.
BALPHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — BALPHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
BALPHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for BALPHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
BALPHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for BALPHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in BALPHARMA stood at 59.2% of traded volume, against a 20-day average of 50.2%.
BALPHARMA announcements: results, concalls, ratings, M&A.
Filings BALPHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
BALPHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 59 documents below.
General Updates
Dividend Payment Update - Intimation regarding disbursement of final dividend for the FY 2025 26 and withholding of dividend in respect of…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Bal Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended…
Change in Director(s)
Bal Pharma Limited has informed the Exchange regarding Change in Director(s) of the company.
Shareholders meeting
Bal Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 24, 2026. Further, the company…
Trading Window
Bal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
BALPHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue BALPHARMA has declared, sequenced by announce and record date.
BALPHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About BALPHARMA: business, sector, key facts.
What BALPHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
BALPHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BALPHARMA, BSE: 524824.
Bal Pharma Limited is a pharmaceutical company headquartered in Bengaluru, India, that manufactures and markets a diverse range of pharmaceutical formulations and active pharmaceutical ingredients (APIs) both domestically and internationally. Their product portfolio caters to a broad spectrum of therapeutic areas and consumer needs.
The company's offerings include a wide array of prescription drugs, generic medications, over-the-counter (OTC) products, and intravenous infusion products. This encompasses various therapeutic categories such as anti-infectives, pain management solutions, respiratory care medications, and women's health products, marketed under various brand names including Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel. They also produce diabetic care products (Diabend and Diabend M Group), herbal/ayurvedic preparations for conditions like prostate enlargement, renal calculi, and infertility (Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin), and products addressing cardiovascular health, skin care, and bone health (Secremet and Servace brands).
Beyond finished formulations, Bal Pharma is a significant player in the API market, providing a wide array of active ingredients for numerous therapeutic applications. These APIs support the production of medications targeting conditions such as allergies, inflammation, diabetes, neurological disorders, urinary issues, and acne. The company manufactures diverse dosage forms including tablets, capsules, syrups, suspensions, ophthalmic preparations, creams, and ointments.
Furthermore, Bal Pharma's expertise extends to the treatment of gastrointestinal disorders and conditions like piles, fistula, and constipation. The company's international reach is substantial, with exports spanning approximately 30 countries. Established in 1987, Bal Pharma has grown to become a prominent player in the Indian and global pharmaceutical landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about BALPHARMA (BALPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of BALPHARMA (BALPHARMA)?
The current share price of BALPHARMA (BALPHARMA) is ₹106.79. Today, the stock has gained by ₹1.05 (0.99%), trading in a range of ₹105.11 to ₹109.79. The stock opened at ₹106.95 with a trading volume of 25,522 shares.
02What is the 52-week high and low price of BALPHARMA stock?
The 52-week high price of BALPHARMA (BALPHARMA) is ₹124.60, while the 52-week low is ₹60.00. Currently trading at ₹106.79, the stock is 77.98% above its 52-week low and 14.29% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of BALPHARMA and when is the next dividend?
BALPHARMA offers a dividend yield of 1.36%, which means for every ₹100 invested at the current price of ₹106.79, you can expect to receive approximately ₹1.36 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is BALPHARMA stock performing today in the market?
BALPHARMA stock opened at ₹106.95 and is currently trading at ₹106.79, showing a gain of ₹1.05 (0.99%). The intraday high is ₹109.79 and low is ₹105.11. The trading volume stands at 25,522 shares, indicating moderate market participation today.
05What is the market capitalization of BALPHARMA?
BALPHARMA has a market capitalization of ₹134.21 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹106.79) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of BALPHARMA?
BALPHARMA has a Return on Equity (ROE) of 6.49% and Return on Capital Employed (ROCE) of 9.07%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
07Which sector and industry does BALPHARMA belong to?
BALPHARMA operates in the Healthcare sector and belongs to the Pharmaceuticals industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the debt-to-equity ratio of BALPHARMA?
BALPHARMA has a debt-to-equity ratio of 1.48, which measures the company's financial leverage by comparing total debt to shareholders' equity. A ratio above 1 suggests the company uses more debt than equity for financing. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
The data, ratios and commentary about BALPHARMA (BALPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.